Diabetic Gastroparesis - Drug Pipeline Landscape, 2023

Diabetic Gastroparesis - Drug Pipeline Landscape, 2023

Diabetic Gastroparesis is a serious complication of diabetes resulting in delayed gastric emptying with associated upper gastrointestinal (GI) symptoms in the absence of any mechanical obstruction. Gastroparesis is a digestive disorder with a high incidence among people with long-standing diabetes.

Gastroparesis can cause due to the damage of vagus nerve. Certain medications, such as opioid pain relievers, some antidepressants, and high blood pressure and allergy medications, can lead to slow gastric emptying and cause similar symptoms.

Symptoms of diabetic gastroparesis includes nausea, vomiting and abdominal pain. It can also cause problems with blood sugar levels and nutrition, feeling of fullness after eating just a few bites, vomiting undigested food eaten a few hours earlier, acid reflux, changes in blood sugar levels, lack of appetite, weight loss and malnutrition.

Doctors most often diagnose diabetic gastroparesis by using the tests such as scintigraphy, breath tests, upper gastrointestinal (GI) endoscopy, wireless motility capsule, barium X-ray, gastric manometry, radioisotope gastric-emptying scan.

The most common investigative treatments include metoclopramide (Reglan) and erythromycin. Surgery in some cases may improve outcomes. Symptoms can be eased through lifestyle changes and home remedies like eating smaller meals more frequently, avoid fibrous fruits and vegetables, drink about 34 to 51 ounces (1 to 1.5 liters) of water a day.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Diabetic Gastroparesis treatment such as CNSA-001, NG101, PCS12852. Key players involved in the development of therapies to treat diabetic gastroparesis are Neurograstx Inc, Processa Pharmaceuticals, PTC Therapeutics. Three drugs are under late-stage Phase II clinical trials stages of development.

In December 2022, Processa Pharmaceuticals announced that PCS12852 successfully improved the clinical symptoms associated with gastroparesis in phase 2A trial, further supporting to initiate Phase 2B trial in 2023.

Report Highlights

Global Insight Service's, Diabetic Gastroparesis - Drug Pipeline Landscape, 2023 report provides an overview of the Diabetic Gastroparesis pipeline drugs. This report covers detailed insights on Diabetic Gastroparesis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Diabetic Gastroparesis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

1. Introduction
1.1 Diabetic Gastroparesis- Pipeline Drugs, 2023 - Coverage
2. Disease Overview - Diabetic Gastroparesis
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Diabetic Gastroparesis- Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs - Phase II
5.1.1 CNSA-001
5.1.2 NG101
5.1.3 PCS12852
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 Neurograstx Inc
9.2 Processa Pharmaceuticals
9.3 PTC Therapeutics
10. Dormant Drugs
10.11 Inactive Drugs
10.12 Discontinued Drugs
11. Appendix
List of Tables
Table 1.1 Number of Products under Development by Diabetic Gastroparesis
Table 1.2 Number of Products under Development by Companies
Table 1.3 Products under Development by Companies
Table 1.4 Products by Targets
Table 1.5 Products by Mechanism of Action
Table 1.6 Products by Molecule Type
Table 1.7 Products by Route of Administration
Table 2.1 Clinical Trial Details - CNSA-001/PTC Therapeutics
Table 2.2 Clinical Trial Details - NG101/Neurogastrx Inc
Table 2.3 Clinical Trial Details - PCS12852/Processa Pharmaceuticals
Table 3.1 Regulatory Designations
Table 4.1 Inactive Drugs
Table 4.2 Discontinued Drugs
List of Figures
Figure 1.1 Number of Products under Development for Diabetic Gastroparesis, 2023
Figure 1.2 Products by Top 5 Targets and Stage of Development for Diabetic Gastroparesis, 2023
Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Diabetic Gastroparesis, 2023
Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Diabetic Gastroparesis, 2023
Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Diabetic Gastroparesis, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings